Filtered By:
Condition: Epilepsy
Nutrition: Organic
This page shows you your search results in order of date.
Order by Relevance | Date
Total 92 results found since Jan 2013.
Trends in volume-regulated anion channel (VRAC) research: visualization and bibliometric analysis from 2014 to 2022
Conclusion: The aim of this bibliometric analysis is to provide an overall perspective for research on VRAC. VRAC has become a topic of increasing interest, and our analysis shows that it continues to be a prominent area. This study offers insights into the investigation of VRAC channel and may guide researchers in identifying new directions for future research.PMID:37538172 | PMC:PMC10394876 | DOI:10.3389/fphar.2023.1234885
Source: Atherosclerosis - August 4, 2023 Category: Cardiology Authors: Tianbao Liu Yin Li Dawei Wang Tobias Stauber Jiajun Zhao Source Type: research
Gastrodia elata Blume: A review of its mechanisms and functions on cardiovascular systems
Fitoterapia. 2023 Apr 17:105511. doi: 10.1016/j.fitote.2023.105511. Online ahead of print.ABSTRACTGastrodia elata Blume (GEB), commonly called Tianma in Chinese, is a valuable and extensively used herbal Traditional Chinese Medicine with a wide range of clinical applications. It has been used to treat headaches, dizziness, stroke, epilepsy, amnesia, spasm, and other disorders since ancient times. Hundreds of compounds, including Phenols, glycosides, polysaccharides, steroids, organic acids, and others, have been isolated and identified from this plant. Modern pharmacological studies have shown that its active ingredients p...
Source: Fitoterapia - April 17, 2023 Category: Biochemistry Authors: Xiaoning Sun Bo Jia Jingran Sun Jianguo Lin Bingjiu Lu Jinlong Duan Cheng Li Qingqing Wang Xin Zhang Meng Tan Dongsheng Zhong Xiaoxiao Zhang Ziyi Sun Yan Zhang Kuiwu Yao Source Type: research
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Acori Tatarinowii Rhizoma: A comprehensive review of its chemical composition, pharmacology, pharmacokinetics and toxicity
Acori Tatarinowii Rhizoma (ATR, Shi Chang Pu in Chinese), a natural product with multiple targets in various diseases. This review provides the comprehensive summary of the chemical composition, pharmacological effects, pharmacokinetics parameters and toxicity of ATR. The results indicated that ATR possesses a wide spectrum of chemical composition, including volatile oil, terpenoids, organic acids, flavonoids, amino acids, lignin, carbohydrates and so on. Accumulating evidence from various studies has shown that ATR exerts a wide range of pharmacological properties, including protecting nerve cells, alleviating learning an...
Source: Frontiers in Pharmacology - March 16, 2023 Category: Drugs & Pharmacology Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
A Review on the Arylpiperazine Derivatives as Potential Therapeutics for the Treatment of Various Neurological Disorders
Curr Drug Targets. 2022 Jan 17. doi: 10.2174/1389450123666220117104038. Online ahead of print.ABSTRACTNeurological disorders are disease conditions related to the neurons and central nervous system (CNS). Any kind of structural, electrical, biochemical and functional abnormalities in neurons can lead to various types of disorders like Alzheimer's disease (AD), depression, Parkinson's disease (PD), epilepsy, stroke, etc. Currently available medicines are symptomatic and do not treat the disease state. Thus, novel CNS active agents with the potential of complete treatment of an illness are highly desired. A range of small or...
Source: Epilepsy Curr - March 21, 2022 Category: Neurology Authors: Bhupinder Kumar Naveen Kumar Amandeep Thakur Vijay Kumar Rakesh Kumar Vinod Kumar Source Type: research
